Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Monopar Therapeutics Inc.NASDAQ: MNPR
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) rises 2535.5% from a year ago
Property, plant & equipment (net) stood at $239.88K at the end of Q1 FY2026, up 2535.5% from a year earlier and down 5.9% from the prior quarter. Over 3 fiscal years it compounded at +60.9% a year.
Context
- Property, plant & equipment (net) amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +2535.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 254.92K USD
- Year-over-year change
- —
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 254.92K | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 12.65K | -79.3% |
| FY2022 | 2022-12-31 | 61.23K | — |
| FY2021 | 2021-12-31 | 0 | — |
Property, Plant & Equipment (Net) vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +2535.5% is the highest of 11, against a peer median of -11.8%.
- Property, plant & equipment (net) amounts to 0.2% of total assets for MNPR, versus a peer median of 4.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $86M USD | -8.4% | -1.0% | 11.9% | |
| Sep 2026 | $63.5M USD | +95.6% | — | 5.4% | |
| Mar 2026 | $33.97M USD | -17.1% | -14.5% | 15.6% | |
| Sep 2026 | $20.55M USD | +39.9% | +163.3% | 4.1% | |
| Mar 2026 | $20.27M USD | +31.2% | -12.6% | 3.1% | |
| Mar 2026 | $8.92M USD | +32.3% | +26.6% | 4.3% | |
| Dec 2025 | €4.35M EUR | -15.2% | -20.1% | 6.9% | |
| Mar 2026 | $1.2M USD | -91.0% | -49.8% | 0.4% | |
| Mar 2026 | $1.05M USD | -88.3% | -50.4% | 0.6% | |
| Jun 2026 | $700K USD | -57.8% | -11.3% | 1.7% | |
| Mar 2026 | $239.88K USD | +2535.5% | +60.9% | 0.2% | |
| Peer median (excluding MNPR) | — | -11.8% | -12.6% | 4.2% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.